Show simple item record

dc.contributor.authorBalkus, Jennifer E.
dc.contributor.authorPalanee-Phillips, Thesla
dc.contributor.authorReddy, Krishnaveni
dc.contributor.authorSiva, Samantha
dc.contributor.authorHarkoo, Ishana
dc.contributor.authorNakabiito, Clemensia
dc.contributor.authorKintu, Kenneth
dc.contributor.authorNair, Gonasangrie
dc.contributor.authorChappell, Catherine
dc.contributor.authorMatovu Kiweewa, Flavia
dc.contributor.authorKabwigu, Samuel
dc.contributor.authorNaidoo, Logashvari
dc.contributor.authorJeenarain, Nitesha
dc.contributor.authorMarzinke, Mark
dc.contributor.authorSoto-Torres, Lydia
dc.contributor.authorBrown, Elizabeth R.
dc.contributor.authorBaeten, Jared M.
dc.date.accessioned2022-01-22T05:59:17Z
dc.date.available2022-01-22T05:59:17Z
dc.date.issued2017
dc.identifier.citationBalkus, J. E., Palanee-Phillips, T., Reddy, K., Siva, S., Harkoo, I., Nakabiito, C., ... & Baeten, J. M. (2017). Dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. Journal of acquired immune deficiency syndromes (1999), 76(2), e47. DOI: 10.1097/QAI.0000000000001455en_US
dc.identifier.other10.1097/QAI.0000000000001455
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1418
dc.description.abstractTo evaluate the potential for a clinically relevant drug-drug interaction with concomitant use of a dapivirine vaginal ring, a novel antiretroviral-based HIV-1 prevention strategy, and hormonal contraception by examining contraceptive efficacies with and without dapivirine ring use. A secondary analysis of women participating in MTN-020/ASPIRE, a randomized, double-blind, placebo-controlled trial of the dapivirine vaginal ring for HIV-1 prevention. Methods: Use of a highly effective method of contraception was an eligibility criterion for study participation. Urine pregnancy tests were performed monthly. Pregnancy incidence by arm was calculated separately for each hormonal contraceptive method and compared using an Andersen-Gill proportional hazards model stratified by site and censored at HIV-1 infection. Of 2629 women enrolled, 2310 women returned for follow-up and reported using a hormonal contraceptive method at any point during study participation (1139 in the dapivirine arm, 1171 in the placebo arm). Pregnancy incidence in the dapivirine arm versus placebo among women using injectable depot medroxyprogesterone acetate was 0.43% vs. 0.54%, among women using injectable norethisterone enanthate was 1.15% vs. 0%, among women using hormonal implants was 0.22% vs. 0.69%, and among women using oral contraceptive pills was 32.26% vs. 28.01%. Pregnancy incidence did not differ by study arm for any of the hormonal contraceptive methods. Use of the dapivirine ring does not reduce the effectiveness of hormonal contraceptives for pregnancy prevention. Oral contraceptive pill use was associated with high pregnancy incidence, potentially due to poor pill adherence. Injectable and implantable methods were highly effective in preventing pregnancy.en_US
dc.language.isoenen_US
dc.publisherJournal of acquired immune deficiency syndromesen_US
dc.subjectDapivirineen_US
dc.subjectNNRTIen_US
dc.subjectHormonal contraceptionen_US
dc.subjectPregnancyen_US
dc.titleDapivirine vaginal ring use does not diminish the effectiveness of hormonal contraceptionen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record